Endocan and Asymmetric Dimethylarginine as an Etiological Indicator in the Maternal and Umbilical Cord Serum in Pre-Eclampsia
- 1 September 2021
- journal article
- research article
- Published by Galenos Yayinevi in Medical Bulletin of Haseki
- Vol. 59 (4), 308-312
- https://doi.org/10.4274/haseki.galenos.2021.7101
Abstract
Aim: Preeclampsia is a pregnancy-specific disease of unknown etiology. This study was planned to determine the place of asymmetric dimethylarginine (N, N-dimethylarginine, ADMA) and endothelial cell specific molecule-1 (ESM1, endocan) levels in etiology. The aim of this study was to determine ADMA and endocan levels in maternal and fetal umbilical cord serum of patients with preeclampsia and to evaluate them with clinical data. Methods: This case-control study was conducted between June and December 2020. The clinical and demographic characteristics of the participants were evaluated in the department of obstetrics and gynecology. Thirty-tree women with preeclampsia and 55 healthy women in the same age group were included in our study. Serum ADMA and endocan values were determined by the ELISA method. Results: Maternal and umbilical cord ADMA levels in the preeclampsia group were statistically significantly higher than the control group (p=0.001, p=0.001, respectively). Likewise, the levels of the umbilical cord and maternal serum endocan were statistically significantly higher in the preeclampsia group compared to the control group (p=0.001, p=0.037, respectively). Conclusion: We found that ADMA and endocan molecules associated with endothelial dysfunction in the pathogenesis of preeclampsia significantly increased in maternal and umbilical cord serum.Keywords
This publication has 21 references indexed in Scilit:
- Possible role of asymmetric dimethylarginine (ADMA) in prediction of perinatal outcome in preeclampsia and fetal growth retardation related to preeclampsiaThe Journal of Maternal-Fetal & Neonatal Medicine, 2016
- Serum levels of endocan correlate with the presence and severity of pre-eclampsiaClinical and Experimental Hypertension, 2015
- Endocan-1 concentrations in maternal and fetal plasma and placentae in pre-eclampsia in the third trimester of pregnancyCytokine, 2015
- First-Trimester Maternal Serum Levels of sFLT1, PGF and ADMA Predict PreeclampsiaPLOS ONE, 2015
- Serum endocan concentration in women with pre-eclampsiaArchiv für Gynäkologie, 2014
- Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney diseaseKidney International, 2014
- Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromesThe Journal of Maternal-Fetal & Neonatal Medicine, 2014
- Pre-eclampsiaThe Lancet, 2010
- The Role of Nitric Oxide Synthase Inhibition by Asymmetric Dimethylarginine in the Pathophysiology of PreeclampsiaGynecologic and Obstetric Investigation, 2009
- Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infantsAmerican Journal of Obstetrics and Gynecology, 2008